Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Saved in:
| Title: | Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. |
|---|---|
| Authors: | Ramirez-Ardila DE; Department of Medical Oncology, Erasmus MC Cancer Institute, Room Be424, PO Box 2040, 3000 CA, Rotterdam, The Netherlands., Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2013 May; Vol. 139 (1), pp. 39-49. Date of Electronic Publication: 2013 Apr 17. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
